News & Updates
Showing Oncology articles
Showing

Psilocybin shows promise in relieving depression in cancer patients
The 5-HT2A receptor agonist psilocybin, when taken under medical supervision, may offer a promising approach to treatment of major depressive disorder (MDD) in cancer patients, results of a small phase II study suggest.

Immune-related AEs predict survival in cancer patients on ICI
Developing cutaneous immune-related adverse events (cirAEs) among advanced cancer patients on immune checkpoint inhibitor (ICI) appears to be a sign of longer overall survival, particularly in those with melanoma, suggests a recent study.

Surgery, but not chemo, may benefit patients with rare ovarian neoplasms
Good quality surgery conferred a progression-free survival (PFS) benefit for women with ovarian sex cord stromal tumours (SCST) in the first-line setting and on first and second relapse. Chemotherapy, on the other hand, had no impact on survival in the first-line or relapse setting.

Immune-related AEs tied to improved survival in bladder cancer patients on atezolizumab
In patients with locally advanced or metastatic urothelial cancer patients receiving atezolizumab treatment, immune-related adverse events (AEs) were associated with improved survival outcomes, according to an analysis of individual participant data from the IMvigor210 and IMvigor211 studies.





